AG-946

DRUG3 trials

Sponsors

Agios Pharmaceuticals Inc., Agios Pharmaceuticals, Inc.

Conditions

Anemia Due to Lower-Risk Myelodysplastic SyndromesAnemia, Sickle CellHealthy VolunteersSickle Cell Disease

Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

CompletedNCT04536792

Agios Pharmaceuticals, Inc.Anemia, Sickle Cell, Healthy Volunteers

Start: 2020-07-10End: 2023-12-19Updated: 2024-04-16

Phase 2

A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes

RecruitingCTIS2022-500609-42-00

Agios Pharmaceuticals Inc.Anemia Due to Lower-Risk Myelodysplastic Syndromes

Start: 2023-02-24Target: 78Updated: 2025-12-09

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose-Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease

RecruitingCTIS2024-519746-70-01

Agios Pharmaceuticals Inc.Sickle Cell Disease

Start: 2025-09-15Target: 20Updated: 2025-07-18

Related Papers

Results from a Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tebapivat (AG-946) in Patients with Sickle Cell Disease

Blood2024-11-052 citations

Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease

Blood2023-11-02

Results from the Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Blood2022-11-157 citations

Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Blood2021-11-052 citations